| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CGEM | Common Stock | Sale | -$12.6K | -432 | -0.18% | $29.06 | 245K | Sep 16, 2021 | Direct | F1, F2 |
| transaction | CGEM | Common Stock | Sale | -$90.8K | -3.12K | -0.04% | $29.06 | 7.65M | Sep 16, 2021 | See Footnote | F1, F2, F3, F4 |
| Id | Content |
|---|---|
| F1 | Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.14 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F3 | These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. |
| F4 | The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. |